Acrycoat S12.5 represents a high-performance anionic acrylic copolymer film supplied as a 12% clear solution in isopropanol, specifically designed for sustained-release pharmaceutical applications. This advanced polymer formulation complies with stringent USP/NF and EP specifications for Methacrylic Acid Copolymer Type B, ensuring global regulatory acceptance and quality assurance. The film exhibits excellent physical characteristics as a colorless, transparent, and brittle coating material, with optional pigmented variants available for specific formulation requirements. Its unique pH-dependent solubility profile maintains insolubility in gastric fluids and natural juices while achieving free solubility in intestinal environments at pH 7.0 and above through salt formation with alkalis, providing precise control over drug release timing and location for optimal therapeutic effect.

This specialized polymer finds extensive application across the pharmaceutical industry for developing an...

Acrycoat S12.5 represents a high-performance anionic acrylic copolymer film supplied as a 12% clear solution in isopropanol, specifically designed for sustained-release pharmaceutical applications. This advanced polymer formulation complies with stringent USP/NF and EP specifications for Methacrylic Acid Copolymer Type B, ensuring global regulatory acceptance and quality assurance. The film exhibits excellent physical characteristics as a colorless, transparent, and brittle coating material, with optional pigmented variants available for specific formulation requirements. Its unique pH-dependent solubility profile maintains insolubility in gastric fluids and natural juices while achieving free solubility in intestinal environments at pH 7.0 and above through salt formation with alkalis, providing precise control over drug release timing and location for optimal therapeutic effect.

This specialized polymer finds extensive application across the pharmaceutical industry for developing and manufacturing oral sustained-release medications. Pharmaceutical companies, contract development and manufacturing organizations, and generic drug producers utilize Acrycoat S12.5 primarily in matrix systems through dry granulation methods to create reliable delayed-release formulations. The product serves as an essential excipient for enteric-coated tablets that safeguard active pharmaceutical ingredients from stomach acid while ensuring targeted release in the intestinal tract. Its compliance with international pharmacopeial standards makes it particularly valuable for companies operating in global markets and export-oriented pharmaceutical manufacturing, providing a standardized solution that meets diverse regulatory requirements across different geographical regions.

Acrycoat S12.5 delivers substantial business value through its proven reliability and consistent performance in demanding pharmaceutical manufacturing environments. The product's exceptional batch-to-batch consistency minimizes formulation risks and streamlines production processes, reducing variability and enhancing manufacturing efficiency. Available in both clear and pigmented forms, it offers formulation flexibility to meet specific functional and identification requirements without compromising performance. This combination of reliability, versatility, and global compliance makes it a preferred choice for pharmaceutical companies seeking to develop effective sustained-release formulations while maintaining regulatory compliance and manufacturing excellence, ultimately supporting the creation of superior pharmaceutical products that meet evolving market demands.

Key Features:
- USP/NF & EP compliant Methacrylic Acid Copolymer Type B formulation
- pH-dependent solubility: insoluble in gastric fluid, soluble at intestinal pH 7.0+
- Available in colorless transparent film and pigmented variants
- 12% clear solution in isopropanol for easy application
- Designed for matrix method sustained-release systems via dry granulation

Benefits:
- Ensures precise drug delivery through reliable pH-dependent release mechanism
- Provides global regulatory compliance with USP/NF & EP standards
- Offers formulation flexibility with clear and pigmented options
- Enhances manufacturing efficiency with consistent batch-to-batch performance
- Supports targeted intestinal release while protecting drugs from gastric degradation